Reuters Health Information: Portal vein embolization leads to liver growth before resection of hamartoma
Portal vein embolization leads to liver growth before resection of hamartoma
Last Updated: 2015-09-23
By Will Boggs MD
NEW YORK (Reuters Health) - Portal vein embolization
produced liver growth prior to hepatic resection of a
mesenchymal hamartoma in a toddler, according to a case report.
In adults, portal vein embolization induces hypertrophy of
the future liver remnant before extended hepatectomy, thereby
decreasing the risk of postoperative liver failure. This
approach has not been reported before in children.
Dr. Sylvain Terraz from Swiss Center for Liver Diseases in
Children, University Hospitals of Geneva, and colleagues
performed portal vein embolization percutaneously in a
14-month-old toddler with a large multifocal mesenchymal
hamartoma of the entire right liver.
Five weeks after embolization, the future liver remnant
volume had increased from 104 mL to 216 mL, a gain of 108%, and
now represented 42.6% of the overall liver volume.
In contrast, a nonembolized segment increased in volume by
only 8% during the same interval, according to the report,
online September 21 in Pediatrics.
After right hepatectomy, total bilirubin and factor V
activity remained within normal ranges, and four years later the
child was thriving and doing well.
Yearly Doppler ultrasound studies have shown normal liver
parenchyma and normal flow of the hepatic vessels, without bile
duct dilatation.
"Portal vein embolization is feasible in very young children
when an extended liver resection is indicated," the authors
conclude. "However, there is a need to develop appropriate
(embolic) materials for pediatric patients, to warrant the
safety profile of this procedure."
Dr. Uenis Tannuri from the University of São Paulo Medical
School's Pediatric Surgery and Pediatric Liver Transplantation
Division in Brazil has performed more than 650 pediatric liver
transplants.
"Generally, I do not recommend this procedure previously to
a hepatectomy," Dr. Tannuri, who is not linked to the new
report, told Reuters Health by email.
"Hepatectomies for mesenchymal hamartomas may be easily
performed, without complications. It is a benign tumor! Extended
right hepatectomy is very easy to perform, with liver remnant of
segments 2 and 3 and excellent postoperative liver function. You
can resect up to 4/5 of liver parenchyma, without postoperative
liver dysfunction," he said.
"In my opinion, this complex procedure (portal vein branch
embolization) is feasible, although unnecessary," Dr. Tannuri
concluded.
Dr. Sajid S. Qureshi from Tata Memorial Hospital's division
of pediatric surgical oncology in Mumbai, India, told Reuters
Health by email, "Portal vein embolization can be recommended in
any age if there is a genuine indication to enhance the residual
unaffected liver volume prior to extensive resection."
Like Dr. Tannuri, though, he noted that "children can
withstand resection of their liver parenchyma. Hence, if one is
confident of having a safe resection, it can be performed even
in large tumors without portal vein embolization. Secondly,
mesenchymal hamartomas are benign tumors and don't require
aggressive resection; therefore, a conservative resection is
advisable and is feasible in most instances if the vascular
anatomy permits."
Dr. Terraz did not respond to a request for comments.
SOURCE: http://bit.ly/1NSW0MG
Pediatrics 2015.
|